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KEY PO INT S
l Azacitidine
maintenance is
feasible in intensively
treated older patients
with newly
diagnosed AML.
l Azacitidine
maintenance, with
adjustment for poor
risk cytogenetic risk
at diagnosis and
platelet count at
randomization,
improves DFS.
The prevention of relapse is the major therapeutic challenge in older patients with acute
myeloid leukemia (AML) who have obtained a complete remission (CR) on intensive che-
motherapy. In this randomized phase 3 study (HOVON97) in older patients (‡60 years) with
AML or myelodysplastic syndrome with refractory anemia with excess of blasts, in CR/CR
with incomplete hematologic recovery (CRi) after at least 2 cycles of intensive chemo-
therapy, we assessed the value of azacitidine as postremission therapy with respect to
disease-free survival (DFS; primary end point) and overall survival (OS; secondary end point).
In total, 116 eligible patients were randomly (1:1) assigned to either observation (N 5 60)
or azacitidine maintenance (N 5 56; 50 mg/m2, subcutaneously, days 1-5, every 4 weeks)
until relapse, for a maximum of 12 cycles. Fifty-five patients received at least 1 cycle of
azacitidine, 46 at least 4 cycles, and 35 at least 12 cycles. The maintenance treatment with
azacitidine was feasible. DFS was significantly better for the azacitidine treatment group
(logrank; P 5 .04), as well as after adjustment for poor-risk cytogenetic abnormalities at
diagnosis and platelet count at randomization (as surrogate for CR vs CRi; Cox regression;
hazard ratio, 0.62; 95% confidence interval, 0.41-0.95; P 5 .026). The 12-month DFS was
estimated at 64% for the azacitidine group and 42% for the control group. OS did not differ between treatment groups,
with and without censoring for allogeneic hematopoietic cell transplantation. Rescue treatment was used more often
in the observation group (n 5 32) than in the azacitidine maintenance group (n 5 9). We conclude that azacitidine
maintenance after CR/CRi after intensive chemotherapy is feasible and significantly improvesDFS. The study is registered
with The Netherlands Trial Registry (NTR1810) and EudraCT (2008-001290-15). (Blood. 2019;133(13):1457-1464)
Introduction
About 75% of patients with acute myeloid leukemia (AML) are
60 years of age or older.1 After intensive chemotherapy, complete
remission (CR) rates in the range of 40% to 55% are generally
attained, resulting in median disease-free survival (DFS) of
between 6 and 12 months.2-8 The prevention of relapse is the
major therapeutic challenge in older patients with AML who
are in CR after intensive chemotherapy. No postremission treat-
ment to prevent relapse has been established and gener-
ally accepted in this setting, except for the use of allogeneic
hematopoietic cell transplantation (allo-HCT) for a selected group
of relatively fit patients.9-11 Although there is a long-standing in-
terest in maintenance therapies such as interleukin 2,12-14 low-
dose cytarabine,15 and gemtuzumab ozogamicin16 after intensive
induction treatment, the clinical benefits of such maintenance
therapy have remained controversial.17
Potential candidates for maintenance treatment include hypo-
methylating agents such as decitabine and azacitidine, which
have proven efficacy and limited extra medullary toxicity in older
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individuals.18-20 A small randomized study comparing decitabine
(20 mg/m2 for 5 days every 4-8 weeks) with conventional care
(observation, low-dose cytarabine or intensive chemotherapy)
was prematurely discontinued without showing a lower relapse
rate for the 20 patients in the decitabine group.21 A phase 2
study exploring decitabine maintenance (20 mg/m2 for 4-5 days
every 6 weeks for 8 cycles) in 134 younger patients with AML in
CR1 did not show better DFS compared with historical controls
(1- and 3-year DFS, 79% and 54%, respectively).22 Various other
small studies involving small numbers of patients explored
azacitidine maintenance, but did not yield any conclusive data
on its usefulness.23,24
Here we present the final analysis of the HOVON97 study. In this
phase 3 study in older patients ($60 years) with AML or MDS-
refractory anemia with excess of blasts, subjects in CR/CR with
incomplete hematologic recovery (CRi) after at least 2 cycles of
intensive chemotherapy were randomly assigned to receive
either azacitidine as postremission therapy or no further treat-
ment (observation). The aim was to assess the value of main-
tenance treatment with respect to DFS (primary end point) and
overall survival (OS; secondary end point).
Methods
Study design and treatment
In this study of the Dutch-Belgian Hemato-Oncology Co-
operative Group (HOVON97), patients who had entered CR or
CRi after at least 2 cycles of remission-induction chemotherapy
were randomly assigned to 12 cycles of azacitidine (50 mg/m2
subcutaneously for 5 days every 4 weeks) or to observation (no
further treatment). Randomizations were balanced by minimi-
zation with the factors hospital, platelet count (,100 3 109/L
vs $100 3 109/L) at randomization, and cytogenetic risk at
diagnosis (favorable/intermediate vs unfavorable). Between
30 June 2009 and 1 December 2016 a total of 118 patients were
registered in the study. Two patients were considered ineligible
(1 was registered twice; the second patient had no CR/CRi), so
that a total of 116 eligible patients were randomized and in-
cluded in the analyses. Azacitidine was provided free of charge
by Celgene. The study was approved by the ethics committees
of the participating institutions, and was conducted in accordance
with the Declaration of Helsinki. The HOVON97 study is regis-
tered with The Netherlands Trial Registry (NTR1810) and EudraCT
(2008-001290-15). The database was locked on July 12, 2018.
Eligibility
Patients with an initial cytopathologically confirmed diagnosis of
AML (M0-M2 and M4-M7) and a minimum of 20% blast infiltrate
in the bone marrow, who were 60 years of age or older, were
eligible, provided they had a World Health Organization (WHO)
performance status of 2 or less and had given their written in-
formed consent and had less than 5% bone marrow blasts after
2 cycles of induction chemotherapy. Eligibility also included an
initial subtype of the MDS (ie, refractory anemia with excess of
blasts) with an International Prognostic Scoring System score of
1.5 or higher and less than 5% bone marrow blasts after 2 cycles
of induction chemotherapy. Patients with extramedullary disease,
AML after previous polycythemia rubra vera or primary myelofi-
brosis, blast crisis of CML or AML-FAB-M3, or AML with cytoge-
netic abnormality t15,17, and patients with a concurrent severe
and/or uncontrolled medical condition or cardiac dysfunction were
considered not eligible. For randomization, postremission patients
were required to be in CR/CRi after at least 2 cycles of intensive
chemotherapy, and to have an absolute neutrophil count greater
than 0.5 3 109/L and a platelet count greater than 50 3 109/L.
Patient characteristics and classification
On the basis of karyotype at diagnosis, patients were classified
into distinct prognostic categories. Patients with core binding
factor abnormalities [t8,21(q22;q22), inv16(p13.1q22), or t16,
16(p13.1;q22)] were classified as favorable risk. Patients without
cytogenetic abnormalities or with loss of X or Y as the only
abnormality were classified as normal cytogenetics. Patients with
complex karyotypes [$3 abnormalities; 25(q), 27(q), abn (3q)]
were classified as unfavorable risk. The remaining patients with
AML were classified as intermediate risk.
Statistical analysis, criteria of response, and
evaluation of outcome
The primary objective of this study in postremission patients was
to compare the value, in relation to DFS, of azacitidine therapy
(intervention group) and no further therapy (observation group).
DFS was measured from the date of randomization to relapse
or death from any cause, whichever came first. Cox regression
analysis with adjustment for the stratification factors (except
center) was the primary analysis for this comparison. According
to the protocol, bone marrow aspirate had to be performed after
24 weeks (observation group) or after 6 cycles (azacitidine group),
and in case of suspicion of relapse (in both groups). The com-
pliance to these bone marrow evaluations was fairly reasonable,
with 7 patients (observation) vs 8 patients (azacitidine) of whom no
bone marrow aspirate was performed at approximately 6 months.
Secondary objectives were to evaluate the effects of azacitidine
after remission in relation to OS measured from the date of
randomization, probability of relapse and death after inclusion
from date of randomization (calculated as competing risks), and
number and duration of hospitalizations, transfusion require-
ments (red cell and platelet transfusion), and adverse events. CR
was defined as a cellular marrow with less than 5% blasts, no
Auer rods, no evidence of extramedullary leukemia, and pe-
ripheral granulocyte and platelet counts of at least 1.0 3 109/L
and 100 3 109/L, respectively. CRi was defined as CR except
for residual neutropenia (,1.0 3 109/L) or thrombocytopenia
(,100 3 109/L). Relapse was defined as recurrence of leukemia
after CR or CRi. OS was measured from the date of registration
until death from any cause. Patients known to be still alive at the
date of last contact were then censored.
Based on our experience with the previous HOVON43 study, in
the present study, we estimated that 40% of patients in the ob-
servation group would have a DFS of 12 months.2 We hypoth-
esized that 60% of patients in the azacitidine maintenance group
would have a DFS of 12 months. A target number of 126 patients,
with 97 events required, would give a power of 80% to detect this
difference with a 2-sided test at 5% significance level, an accrual
period of 3 years, and an additional follow-up of 1 year.
All analyses were performed according to intention to treat,
irrespective of protocol compliance. The log-rank test and Cox
regression analysis were used to analyze the differences between
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both groups with respect to OS and DFS. These analyses were
performed without and with adjustment for platelet count
(,100 vs $100) at randomization and cytogenetic risk classi-
fication at diagnosis. All P values reported are 2-sided.
Possible heterogeneity of the treatment effects between sub-
groups (poor-risk cytogenetic abnormalities at diagnosis [yes vs
no], platelet count [$100 vs ,100 3 109/L] at randomization,
age [younger vs older than median age 69 years], cycles to
CR/CRi [1 vs 2], and performance status [0 vs $1]) were explored.
For each of the variables, a multivariate Cox regression with
treatment group, variable, and treatment group 3 variable
interaction term was performed. Only if the hazard ratio (HR) for
the interaction term was statistically significant different from
1 (P , .05) were subgroup analyses performed. Otherwise,
subgroup analyses were not warranted, and the estimate of
the overall treatment effect also was considered the best
estimate for the treatment effect within a specific subgroup.
Results
Patient cohort
The study was terminated before the accrual of the planned
126 patients. Because of declining accrual of new patients, it was
Table 1. Patient characteristics
Observation group (N 5 60) Azacitidine group (N 5 56)
Sex, male/female 33/27 (55%/45%) 35/21 (63%/37%)
Age, median/range 69/60-79 69/64-81
WHO performance
WHO 0 23 (38%) 29 (52%)
WHO 1 34 (57%) 17 (30%)
WHO 2 — 5 (9%)
Unknown 3 (5%) 5 (9%)
Unfavorable risk cytogenetic abnormalities at
diagnosis*
14 (23%) 9 (16%)
CR(i) obtained after
Induction cycle 1 45 (75%) 35 (63%)
Induction cycle 2 15 (25%) 21 (37%)
Platelet count $100 3 109/L 45 (75%) 38 (68%)
Neutrophils, 3109/L
Median 4.1 3.3
Range 1.5-38 0.6-13.7
CR 45 (75%) 37 (66%)
MDS-refractory anemia with excess of blasts 6 (10%) 6 (11%)
All characteristics were obtained from randomization except unfavorable risk cytogenetic abnormalities, which were obtained at diagnosis.
*27, 27q, 25, 25q, abn 3q, complex $3 abnormalities.
Arm A Arm B
No maintenance
Azacitidine
maintenance
50 mg/m2, day 1-5 q 4 wks
until relapse for a
maximum of 12 cycles
R
Patients with 
AML (except FAB M3 or t(15;17)) or MDS 
RAEB with IPSS ≥1.5 who are sixty years or older 
and have <5% bone 
marrow blasts after 2 cycles 
of (intensive) chemotherapy
Figure 1. Trial design. IPSS, International Prognostic
Scoring System.
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estimated that the number of events, as defined in the original
statistical plan, could not be reached within a reasonable time.
The median follow-up time of the 116 evaluable and eligible
patients still alive at the date of the last contact since the date of
randomization was 41.4 months. Table 1 presents the charac-
teristics of the patients enrolled in the observation and azacitidine
maintenance groups.
Feasibility of azacitidine maintenance treatment
After randomization, 60 patients were assigned to the obser-
vation group and 56 patients to the azacitidine maintenance
group (Figure 1). Because 1 patient had a relapse between
randomization and start of azacitidine postremission treatment,
55 patients started azacitidine cycles 1 to 4. Subsequently,
44 patients started cycles 5 to 8 of azacitidine treatment, and
37 patients started cycles 9 to 12. After 4 cycles, 11 patients went
off protocol (5 relapse, 2 no compliance, 2 hypoplastic bone
marrow, 1 excessive extra-medullary toxicity, and 1 other rea-
son); after 4 additional cycles, another 7 patients went off
protocol (6 relapse, 1 other reason), and finally, after 12 cycles,
37 patients went off protocol (1 relapse, 1 other reason, 35 protocol
completion). This is illustrated in the CONSORT flow diagram
(Figure 2). Interestingly, in the azacitidine group, 35 (63%) of
56 patients completed protocol treatment, whereas in the
observation group, this was feasible (ie, alive without relapse
on protocol) in 23 (38%) of 60 patients.
The adherence to treatment according to the protocol was high.
On average, 90% of the azacitidine cycles were given full dose
according to schedule (mean, 90%; range, 81%-97%). The time
intervals between 2 consecutive cycles was were 30 days for, on
average, 86% of the cycles (mean, 86%; range, 76%-90%) and
between 30 and 40 days for, on average, 10% of the cycles
(median, 10%; range, 7%-14%).
Azacitidine maintenance was associated with a low transfusion
dependence, a limited number of nights in the hospital, and
a limited number of adverse events (AEs) and serious AEs (SAEs)
Randomized
n=118
Randomized &
eligible
n=116
Observation 5-8
n=39 65%
month 5 n=39
month 6 n=36
month 7 n=32
month 8 n=30
Observation 9-12
n=29 48%
month   9 n=29
month 10 n=26
month 11 n=23
month 12 n=23
cycles 5-8
n=44 80%
5 cycles  n=44
6 cycles n=43
7 cycles n=40
8 cycles n=38
cycles 9-12
n=37 67%
  9 cycles n=37
10 cycles n=37
11 cycles n=37
12 cycles n=35
relapse               n=17
death                 n=1
major prot.viol.  n=1
other                  n=2
off protocol n=21 35%
off protocol  n=10  17%
relapse         n=10
not eligible n=2
      double reg. n=1
5% blast    n=1
off protocol n=1
      relapse n=1
relapse                    n=5
no compliance                   n=2
hypoplastic BM abnorm    n=2
excessive extramedullary
drug toxicity                n=1
other          n=1
off protocol n=11 20%
off protocol n=7  13%
relapse n=6
other n=1
off protocol  n=29  48%
relapse  n=5
death  n=1
normal completion    n=23
off protocol  n=37  67%
relapse  n=1
normal completion n=35
other  n=1
Arm A Arm B
Observation 1-4
n=60 100%
month 1 n=60
month 2 n=57
month 3 n=53
month 4 n=47
cycles 1-4
n=55 100%
1 cycle  n=55
2 cycles n=51
3 cycles n=47
4 cycles n=46
Figure 2. CONSORT study diagram. Arm A, observation; Arm B, azacitidine maintenance. The main reason for failure to complete protocol was intercurrent relapse.
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(Table 2; supplemental Table 1, available on the BloodWeb site).
Red blood cell transfusions were not given to 92% of control
patients and 86% of patients in the azacitidine group, whereas
93% and 86%, respectively, did not require any platelet trans-
fusions. Furthermore, 92% of patients in the observation group
and 86% in the azacitidine treatment group did not require
clinical hospital admission. The number of AEs and SAEs were
also comparable between both groups: 93% of patients in the
observation group and 75% of those in the azacitidine treatment
group did not experience any SAEs (ie, 4 patients in observation
group and 14 patients in the azacitidine group experienced
SAEs).
Treatment outcome according to
postremission randomization
DFS was significantly improved after azacitidine maintenance
treatment (64% vs 42% at 12 months; logrank; P5 .04; Figure 3).
DFS at 24 and 36 months was estimated at 44% and 32% for the
azacitidine group and 20% and 16% for the control group, re-
spectively. Cox regression analysis, with adjustment for poor-risk
cytogenetic abnormalities at diagnosis and platelet count of
at least 100 3 109/L (according to protocol), confirmed the
significant improvement in DFS after azacitidine maintenance
(Cox regression; HR, 0.62; 95% confidence interval, 0.41-0.95;
P 5 .026).
Multivariate Cox regression analysis was performed to in-
vestigate possible heterogeneity of the treatment effects (DFS)
between subgroups (poor-risk cytogenetic abnormalities at di-
agnosis [yes vs no], platelet count [$100 vs ,100 3 109/L], age
[younger vs older than median age 69 years], response CR[i]
reached after induction cycle 1 vs induction cycle 2, cycles to
CR/CRi [1 vs 2], performance status [0 vs$ 1]). Only a statistically
significant interaction between treatment group and platelet
count was found, which revealed that patients with a platelet
count of at least 100 3 109/L at inclusion (and not those with
a platelet count,1003 109/L) had a significant better DFS after
azacitidine maintenance (supplemental Figure 2). In line with
this, a significant interaction between treatment group and CR
(and not CRi) was observed (supplemental Figure 3).
This significant improvement in DFS did not translate to a sig-
nificant improvement in OS (84% vs 70% at 12 months; logrank;
P 5 .69) (Figure 4). Cox regression analysis confirmed the lack
of improvement in OS after azacitidine maintenance (Cox re-
gression; HR, 0.91; 95% confidence interval, 0.58-1.44; P5 .69).
At the same time, we noted an imbalance in the use of salvage
therapy after relapse between the study groups. Thirty-two
Table 2. Feasibility and safety
Observation group (N 5 60) Azacitidine group (N 5 56)
Transfusion requirements
RBC (median/mean), units 0/1 0/1
No. of patients receiving no RBC 55 (92%) 48 (86%)
Platelets, median/mean 0/1 0/1
Patients receiving no platelets, n 56 (93%) 48 (86%)
Nights in hospital
Median/mean 0/1 0/2
Patients without nights in hospital, n 55 (92%) 48 (86%)
AEs
Median 1 2
AE $2 grade (total), n 449 510
Patients with SAEs
0 SAE 56 (93%) 42 (75%)
1 SAE 4 (7%) 11 (20%)
2 SAE 2 (3%)
3 SAE 1 (2%)
RBC, red blood cells.
100
75
50
25
0
0 6 12 18
Disease free survival from CR/CRi
24
Time
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m
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armA
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Cox LR P =0.04
N
60
56
F
49
44
60
56
armA
armB
At risk:
35
46
25
36
13
23
10
23
7
17
armB
armA
Figure 3. Kaplan-Meier estimates for DFS. armA, observation group; armB,
azacitidine maintenance group. Azacitidine maintenance treatment increased
the median DFS by 5.6 months (armA, 10.3 months; armB, 15.9 months).
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patients in the control group (7 azacitidine, 19 other chemo-
therapy, 6 other treatment) and 9 patients in the azacitidine
maintenance group (5 other chemotherapy, 4 other treatment)
received rescue treatment after relapse while on protocol. In
total, 87 patients relapsed until database lock (including relapses
that occurred off protocol). The OS, as expected, was signifi-
cantly better in those 86 relapsed patients (1 patient was lost
to follow-up) who received rescue treatment (P , .001). When
considering patients in each group separately, the effect of rescue
treatment was observed in the relapsed patients in both the
control group (P 5 .005) and the azacitidine maintenance group
(P5 .03; supplemental Figure 1). Apparently, maintenance with
azacitidine did not result in resistance for rescue treatment.
Allo-HCT was used after relapse in 11 patients in the observation
group and in 4 patients in the azacitidine maintenance group.
After censoring patients for allo-HCT, no significant difference in
OSwas apparent between the groups (82% vs 63% at 12months;
logrank; HR, 0.76; 95% confidence interval, 0.49-1.17; P5 .209)
(Figure 4).
Discussion
The results of this study represent the first evidence from
a randomized trial indicating that maintenance treatment with
azacitidine significantly improves DFS for older patients with
AML in CR/CRi after intensive remission-induction chemother-
apy. Safety benchmarks such as protocol adherence, transfusion
requirements, nights in hospital, and SAEs confirm the feasibility
and efficacy of applying azacitidine maintenance treatment at
a dose of 50 mg/m2 subcutaneously for 5 days every 28 days.
In general, CRs obtained after remission-induction chemother-
apy in patients aged 60 years and older are short lived, and these
CRs result in an OS of approximately 10% at 5 years from di-
agnosis. In recent years, various efforts have been undertaken to
prevent relapse after CR, with limited success. Also, high-dose
Ara-C consolidation schedules have failed to produce better
outcomes in patients aged at least 60 years.25 Low-dose Ara-C
(10mg/m2 subcutaneously, twice daily, for 12 days) maintenance
treatment has been shown to result in a modest (but significant)
improvement of DFS but not OS.15 A study with rIL-2/histamine
dihydrochloride showed a statistically significant benefit in DFS
without a difference in OS.12 A recent study reported that main-
tenance therapy with norethandrolone significantly improves sur-
vival in elderly patients with AML without increasing toxicity.26
Studies evaluating gemtuzumab ozogamicin and rIL2 provided
no indication for a survival advantage.12-14,16,17 Recent studies in
patients aged 60 years or younger suggest benefits from main-
tenance therapy with the tyrosine kinase inhibitors midostaurin
and sorafenib in FLT3-mutated AML.27,28 The effect of sorafenib
maintenance treatment in older patients with AML has not been
elucidated, as only 8 patients in the sorafenib group completed
maintenance in a placebo-controlled randomized trial involving
older patients with AML.29
Several previous studies have shown that azacitidine is well
tolerated and has single-agent activity in AML and MDS, which
was the basis for the present study on the value of maintenance
treatment with azacitidine. Therefore, we considered mainte-
nance treatment with azacitidine after intensive induction che-
motherapy to be a potentially interesting option, especially for
patients in CRwho are not candidates for allo-HCT. Furthermore,
the use of azacitidine, with its hypomethylating mechanism of
action, after conventional chemotherapy, may result in antileukemic
effects that are additive to the effects of chemotherapy. In-
creasing knowledge about the clonal hierarchy and the fact
that preleukemic HSCs have been identified in remission samples,
which may survive after exposure to chemotherapy, supports
the concept of using azacitidine during maintenance.30,31 In-
deed, our study shows that azacitidine both delays relapse and
prolongs DFS in patients in CR/CRi after 2 cycles of intensive
chemotherapy. These data may support the use of azacitidine
in the clinical management of older pa-tients with AML.
A question that remains is why the improvement in DFS did not
translate into a significant benefit in OS. First, the trial was not
powered to assess differences in OS between treatment groups.
Second, the markedly greater frequency of the use of salvage
treatment at first relapse in the observation group may have
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Figure 4. Kaplan-Meier estimates of OS. (A) OS of all randomized patients
(N 5 116); (B) OS after censoring of 15 patients at allo-HCT (11 in arm A and
4 in arm B). arm A, observation group; arm B, azacitidine maintenance group.
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confounded the analysis of OS. In total, 32 patients in the control
group and 9 patients in the azacitidine group received therapy
after relapse while on study. It is unclear why salvage treatments
were considered less often in the azacitidine group. One possible
explanation is that continued treatment is less commonly con-
sidered in older patients with relapse after two different lines of
treatment.
This study has several limitations, the most important being
the slow accrual and early termination: 7.5 years were needed
to include 118 older patients with AML in CR(i), instead of the
126 patients in the original statistical plan. Other phase 3 studies
on maintenance treatment in older patients with AML also re-
ported relatively low randomization rates.12-17 Apparently, older
patients are less likely to enter treatment protocols of prolonged
duration. In the current study, for instance, the burden of hospital
visits needed for azacitidine injections, after extensive hospi-
talization for intensive chemotherapy, could have been a rea-
son for older patients with AML to refrain from participating in
the study. Therefore, the results on the safety and efficacy of
maintenance with oral azacitidine, which is currently being ex-
plored in a randomized clinical trial in older patients with AML
(NCT01757535), are eagerly awaited. Oral azacitidine may en-
sure better protocol compliance. Furthermore, the results of our
study, with regard to DFS, might have been even better if the
duration of azacitidine was not limited to 1 year, and azacitidine
maintenance had been given until progression, in accordance
with the previous studies on azacitidine treatment.19,20 Another
limitation is the lack of detailed information on the molecular
characterization of the AML blasts and minimal residual disease
(flow and molecular). Although this is now standard practice in
all HOVON AML studies, this was not common practice at the
time when the HOVON97 study was planned. We were therefore
unable to evaluate the effect of azacitidine maintenance within
certain molecular subgroups or on reduction or elimination of
minimal residual disease.
In summary, this study provides the first prospective evidence
for the feasibility and effectiveness of azacitidine maintenance
in newly diagnosed, intensely treated older patients with AML.
It demonstrates that this therapeutic approach significantly
improves DFS.
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